Background: Immune checkpoint inhibitor (ICI) therapy is a fast-developing field within the spectrum of cancer care. ICIs are associated with distinctive immune-related adverse events (irAEs), reflecting their unique mechanisms of action. Objectives: Effective management of irAEs requires early...

Background: Oncology nurses play a significant role in ensuring optimal care coordination for patients receiving immunotherapies. Objectives: The Oncology Nursing Society hosted an immunotherapy summit in March 2018. Summit attendees identified and prioritized several critical resource needs to...

Background: Chimeric antigen receptor (CAR) T-cell therapy program development has regulatory demands and unique operational processes that vary across settings. The infrastructure in which CAR T-cell therapy is implemented has implications for nursing education and competencies. Objectives: This...

Background: Chimeric antigen receptor (CAR) T-cell therapy leverages the power of the patient’s own immune system by serving as a bridge to connect genetically modified T cells to the surface antigens of tumor cells based on targeted ligands. Clinical trials have demonstrated compelling overall...